The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox

Vaccine

Volumn 28, Issue 22, 2010, Pages 3778-3783

  Heinsbroek, Ellen ^a   Ruitenberg, E Joost ^a  

^a ATHENA INSTITUTE   (Netherlands)

Author keywords

Global polio eradication programme; Inactivated polio vaccine; Polio

Indexed keywords

ANTIVIRUS AGENT; CAPSID INHIBITOR; FORMALDEHYDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED POLIOMYELITIS VACCINE; INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPING COUNTRY; DRUG COST; ERADICATION THERAPY; FEASIBILITY STUDY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; VACCINATION; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

DEVELOPING COUNTRIES; HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RISK ASSESSMENT;

EID: 77952320069     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.095     Document Type: Review

References (49)

1. Arita I., Nakane M., and Fenner F. Public health. Is polio eradication realistic?. Science 312 May (5775) (2006) 852-854
2. Global Polio Eradication Initiative. Wild poliovirus weekly update [online] (2010). http://www.polioeradication.org/casecount.asp Case count on 19 January 2010 [cited 22nd January 2010; available from: http://www.polioeradication.org/casecount.asp
3. Roberts L. Polio eradication. Looking for a little luck. Science 323 February (5915) (2009) 702-705
4. Chumakov K., and Ehrenfeld E. New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. Clin Infect Dis 47 December (12) (2008) 1587-1592
5. Chumakov K., Ehrenfeld E., Wimmer E., and Agol V.I. Vaccination against polio should not be stopped. Nat Rev Microbiol 5 December (12) (2007) 952-958
6. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27 May (20) (2009) 2649-2652
7. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec 78 July (28) (2003) 241-250
8. Aylward R.B., Sutter R.W., and Heymann D.L. Policy, OPV cessation-the final step to a "polio-free" world. Science 310 October (5748) (2005) 625-626
9. Tebbens R.J., Pallansch M.A., Kew O.M., Caceres V.M., Jafari H., Cochi S.L., et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 26 December (6) (2006) 1471-1505
10. GPEI. Circulating vaccine-derived poliovirus 2000-2009 (2009). http://www.polioeradication.org/content/general/cvdpv_count.pdf Data as of 24 November 2009 [cited 23rd January 2010; available from: www.polioeradication.org/content/general/cvdpv_count.pdf
11. Update on vaccine-derived polioviruses-worldwide, January 2008-June 2009. MMWR Morb Mortal Wkly Rep 58 September (36) (2009) 1002-1006
12. Roberts L. Polio eradication. Rethinking the polio endgame. Science 323 February (5915) (2009) 705
13. Bonnet M.C., and Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 26 September (39) (2008) 4978-4983
14. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 81 April (15) (2006) 137-144
15. Assembly WH. Resolution WHA61.1. Poliomyelitis: mechanism for management of potential risks to eradication (2008), World Health Organization 61st World Health Assembly, Geneva, Switzerland, May. http://apps.who.int/gb/ebwha/pdf_files/wha61-rec1/a61_rec1-part2-en.pdf http://apps.who.int/gb/ebwha/pdf_files/wha61-rec1/a61_rec1-part2-en.pdf
16. Wyman O. Global post-eradication IPV supply and demand assessment: integrated findings (2009), Bill & Melinda Gates Foundation
17. GPEI. Global Polio Eradication Initiative (2009). http://www.polioeradication.org/ cited 21st October 2009; available from: http://www.polioeradication.org
18. Aylward R.B., and Cochi S.L. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bull World Health Organ 82 January (1) (2004) 40-46
19. Fine P.E., and Ritchie S. Perspective: determinants of the severity of poliovirus outbreaks in the post eradication era. Risk Anal 26 December (6) (2006) 1533-1540
20. Fine P.E., Sutter R.W., and Orenstein W.A. Stopping a polio outbreak in the post-eradication era. Dev Biol (Basel) 105 (2001) 129-147 [discussion 49-50]
21. Barrett S. Polio eradication: strengthening the weakest links. Health Aff (Millwood) 28 July-August (4) (2009) 1079-1090
22. Fine P.E., and Griffiths U.K. Global poliomyelitis eradication: status and implications. Lancet 369 April (9570) (2007) 1321-1322
23. Global Polio Eradication Initiative. FAQs on OPV Cessation (2009). http://www.polioeradication.org/content/fixed/opvcessation/opvc_QA.asp%2313 cited 21st October 2009; available from: http://www.polioeradication.org/content/fixed/opvcessation/opvc_QA.asp#13
24. Mas Lago P., Caceres V.M., Galindo M.A., Gary Jr. H.E., Valcarcel M., Barrios J., et al. Persistence of vaccine-derived poliovirus following a mass vaccination campaign in Cuba: implications for stopping polio vaccination after global eradication. Int J Epidemiol 30 October (5) (2001) 1029-1034
25. Mas Lago P., Gary Jr. H.E., Perez L.S., Caceres V., Olivera J.B., Puentes R.P., et al. Poliovirus detection in wastewater and stools following an immunization campaign in Havana, Cuba. Int J Epidemiol 32 October (5) (2003) 772-777
26. Korotkova E.A., Park R., Cherkasova E.A., Lipskaya G.Y., Chumakov K.M., Feldman E.V., et al. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J Virol 77 December (23) (2003) 12460-12465
27. Zurbriggen S., Tobler K., Abril C., Diedrich S., Ackermann M., Pallansch M.A., et al. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl Environ Microbiol 74 September (18) (2008) 5608-5614
28. Georgescu M.M., Delpeyroux F., Tardy-Panit M., Balanant J., Combiescu M., Combiescu A.A., et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 68 December (12) (1994) 8089-8101
29. Plotkin S. Poliovirus vaccine-inactivated. In: Plotkin S. (Ed). Vaccines. 5th ed. (2008), Saunders Elsevier 605-629
30. WHO. Eliminating needles. the PolioPipeline 1 (2008) 2
31. Lahariya C. Global eradication of polio: the case for "finishing the job". Bull World Health Organ 85 June (6) (2007) 487-492
32. John J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 8 January (1) (2009) 5-8
33. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Bull World Health Organ 74 3 (1996) 253-268
34. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 356 April (15) (2007) 1536-1544
35. Asturias E.J., Dueger E.L., Omer S.B., Melville A., Nates S.V., Laassri M., et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 196 September (5) (2007) 692-698
36. Dayan G.H., Thorley M., Yamamura Y., Rodriguez N., McLaughlin S., Torres L.M., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 195 January (1) (2007) 12-20
37. Fine P.E. Polio: measuring the protection that matters most. J Infect Dis 200 September (5) (2009) 673-675
38. Laassri M., Lottenbach K., Belshe R., Wolff M., Rennels M., Plotkin S., et al. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 192 December (12) (2005) 2092-2098
39. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., and Bernier R.H. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 163 January (1) (1991) 1-6
40. Griffiths U.K., Botham L., and Schoub B.D. The cost-effectiveness of alternative polio immunization policies in South Africa. Vaccine 24 July (29-30) (2006) 5670-5678
41. WHO. Improving IPV. the PolioPipeline 1 (2008) 2-3
42. Arya S.C., and Agarwal N. Inactivated poliovirus vaccine. Hum Vaccin 3 May-June (3) (2007) 71-72
43. WHO. Update on improving IPV. the PolioPipeline 3 (2009) 3
44. WHO. Polio Research Committee outcomes. the PolioPipeline 3 (2009) 1
45. Kreeftenberg H., van der Velden T., Kersten G., van der Heuvel N., and de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 34 June (2) (2006) 155-158
46. WHO. The poliovirus antivirals initiative. the PolioPipeline 3 (2009) 4
47. Collett M.S., Neyts J., and Modlin J.F. A case for developing antiviral drugs against polio. Antiviral Res 79 September (3) (2008) 179-187
48. Dutta A. Epidemiology of poliomyelitis-options and update. Vaccine 26 October (45) (2008) 5767-5773
49. GAVI. GAVI/VF long-term vaccine supply strategy. Recommendations from the GAVI/VF Secretariat (2005). http://www.gavialliance.org/resources/16brd_09._Long_term_supply_strategy.pdf cited 23rd January 2010; available from: http://www.gavialliance.org/resources/16brd_09._Long_term_supply_strategy.pdf